Trastuzumab Deruxtecan Is Active in Desmoplastic Small Round Cell Tumor
- 1 January 2026
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (1)
Abstract
PURPOSE: Desmoplastic small round cell tumor (DSRCT) is a rare sarcoma which remains almost universally fatal despite multimodality therapy. Human epidermal growth factor receptor 2 (HER2) has been identified as a potential therapeutic target prompting HER2-specific investigations and subsequent off-label treatment with fam-trastuzumab deruxtecan (T-DXd) in our DSRCT clinical cohort. METHODS: Fifty-two and 61 DSRCT patient samples were analyzed by immunohistochemical (IHC) assays and RNAseq, respectively. In addition, 19 patients at a single institution with DSRCT in need of therapy underwent IHC testing and RNAseq when feasible and received off-label T-DXd (monotherapy [n = 14], alternating with another agent [n = 2], concomitantly in combination [n = 2]; measurable disease [n = 17], adjuvant setting [n = 2]). RESULTS: HER2 expression levels by RNAseq were analyzed in the context of 346 patients with solid tumor and 23 histologies, with DSRCT having the third highest HER2 expression level overall and a median transcripts per million (TPM) expression level of 41.8 (range, 6.3-116.3). While TMA IHC analyses noted minimal HER2 IHC positivity using 4B5, IHC with clones 29D8 and CB11 uncovered 8.7- to 12.7-fold more HER2 reactivity, respectively. All 17 patients with measurable disease experienced clinical benefit (stable disease or partial response [PR]) with minimal toxicity. In addition, 9 of 17 patients achieved a RECIST PR (53% overall response rate). The response rate did not correlate with available IHC or RNAseq data, and some patients with no membranous IHC expression achieved PR. CONCLUSION: These data show that T-DXd is active in DSRCT and support the planned biomarker-agnostic formal clinical trial with the Children's Oncology Group.Keywords
This publication has 30 references indexed in Scilit:
- Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trialThe Lancet Oncology, 2024
- Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancerVirchows Archiv, 2023
- Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancerNature Communications, 2023
- Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancersNature Communications, 2022
- Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumabGastric Cancer, 2022
- Desmoplastic small round cell tumor is dependent on the EWS-WT1 transcription factorOncogenesis, 2020
- Salmon provides fast and bias-aware quantification of transcript expressionNature Methods, 2017
- RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 TherapyJAMA Oncology, 2017
- Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancerLaboratory Investigation, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009